Showing results (261-270 of 4,634) with videos related to

Sort By:
Pageof 464
Anti-Cancer Drugs|April 15, 2016
MEK inhibitor treatment is effective in a patient with metastatic carcinoma of the ampulla of Vater with BRAF and NRAS mutations shown by next-generation sequencingEsther Tahover, Rachel Bar Shalom, Naama Bogot, et al.
Anti-Cancer Drugs|October 22, 2015
Practical experiences with eribulin in patients with metastatic breast cancerHans Tesch, Andreas Schneeweiss
Anti-Cancer Drugs|August 13, 2015
Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancyYasunori Hashiguchi, Mari Kasai, Takeshi Fukuda, et al.
Anti-Cancer Drugs|August 22, 2015
Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancerOleg Gladkov, Rodryg Ramlau, Piotr Serwatowski, et al.
Anti-Cancer Drugs|April 19, 2016
An open-label, single-arm phase II clinical study of docetaxel plus lobaplatin for Chinese patients with pulmonary and hepatic metastasis of nasopharyngeal carcinomaShuai Zhang, Junni Chen, Shiping Yang, et al.
Anti-Cancer Drugs|August 7, 2018
Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two casesGiuseppe Lombardi, Mario Caccese, Luisa Bellu, et al.
Anti-Cancer Drugs|September 22, 2018
Effects of D-α-tocopherol polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles on the absorption, pharmacokinetics, and pharmacodynamics of salinomycin sodiumJie Li, Liang Zhai, Jiyang Xue, et al.
Anti-Cancer Drugs|September 22, 2018
The nervous system: a new target in the fight against cancerRashek Kazi, Yuri L Bunimovich
Anti-Cancer Drugs|June 8, 2018
DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapyCynthia Bernier, Ahmed Soliman, Michel Gravel, et al.
Anti-Cancer Drugs|August 11, 2018
Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cellsMajid Momeny, Haniyeh Eyvani, Farinaz Barghi, et al.
Pageof 464